evidence
Why BTK Inhibitors Fail Chronic Disease Management?
In 2023, 78% of lupus patients on BTK inhibitors still experienced flare-ups, proving that the drugs alone fail chronic disease management. Without integrated education and self-management tools, the medication’s potential is undermined, leaving patients vulnerable to relapse. Medical Disclaimer: This article is for informational purposes only and does not